Trial Profile
Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Aromatase inhibitors; Cyclophosphamide; Doxorubicin; Paclitaxel; Tamoxifen
- Indications Adenocarcinoma; Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms Alliance
- 06 Jun 2023 Results of pooled analysis from NCT00045032, ISRCTN76560285, NCT00005970, NCT00004067, NCT00054587, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 13 Apr 2022 Results of pooled analysis of NCT00005970, NCT00024102, evaluating Role of age, BMI, and tumor subtype in racial/ethnic disparities in breast cancer survival, presented at the 113th Annual Meeting of the American Association for Cancer Research
- 13 Apr 2022 Results of an analysis assessed the integrated pathological quantification and genomic data to assess functional tertiary lymphoid structure presented at the 113th Annual Meeting of the American Association for Cancer Research